Navigation Links
Dyadic International Reports 2010 Third Quarter Financial Results
Date:11/15/2010

. License fee revenue for the nine months ended September 30, 2010 decreased to $32,000 as compared to approximately $10.2 million for the nine months ended September 30, 2009. The decrease in license fee revenue for the three and nine month periods ended September 30, 2010 as compared to the same periods in 2009 was due to license fee revenue recognized in the third quarter of 2009 of approximately $9.9 million from Codexis, Inc. ("Codexis") pursuant to a non-exclusive license agreement between Codexis and Dyadic.

Research and development revenue for the third quarter ended September 30, 2010 decreased to approximately $64,000 as compared to approximately $298,000 for the third quarter ended September 30, 2009. Research and development revenue for the nine months ended September 30, 2010 decreased to approximately $618,000 as compared to approximately $3.9 million for the nine months ended September 30, 2009. The decrease in research and development revenue for the nine months ended September 30, 2010 as compared to the nine months ended September 30, 2009 was due to research and development revenue recognized in the first quarter of 2009 of approximately $3.3 million from Abengoa Bioenergy R&D, Inc. ("Abengoa") pursuant to a securities purchase agreement between Dyadic and Abengoa.

Net loss for the third quarter ended September 30, 2010 was approximately $1.4 million, or $(0.04) per basic and diluted share as compared to a net loss of approximately $654,000, or $(0.02) per basic and diluted share for the third quarter ended September 30, 2009. Net loss for the nine months ended September 30, 2010 was approximately $3.9 million, or $(0.13) per basic and diluted share as compared to net income of approximately $10.2 million, or $0.34 per basic and $0.31 per diluted share, for the nine months ended September 30, 2009.

At September 30, 2010, cash and cash equivalents were approximately $5.9 million as compared to approximately $8.4 million at
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
2. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
3. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
4. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
5. Dyadic International Engages The Abraham Group as Strategic Advisor
6. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
7. Dyadic International Strengthens Management Team
8. Dyadic International Extends Collaboration With The Scripps Research Institute
9. International Technidyne Corporation Acquired by Warburg Pincus
10. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
11. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... take part in the first half of “Integrative Biotechnology,” an applied biotechnology course ... in summer 2014, this course combines students from both universities and is taught ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender offer ... stock). On June 29, 2015, the last trading day prior to the commencement of ... was $2.29 per share. , The tender offer will expire on July 28, 2015 ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... SAN DIEGO, Jan. 7 Volcano Corporation,(Nasdaq: ... sales of,products for the diagnosis and treatment of coronary ... its previously announced acquisition of,Axsun Technologies, Inc. , ... manufacturer of lasers and optical,engines used in medical Optical ...
... Jan. 7 Sangart, Inc., a privately ... and,commercialization of oxygen-therapeutic agents, today announced a ... key leadership positions and,a significant reduction in ... This restructuring reduces the company,s burn rate ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
Cached Biology Technology:Volcano Announces Closing of Axsun Technologies Acquisition 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 2Sangart, Inc. Announces Key Executive Appointments and Company Restructuring 3Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... RALEIGH, NC Methyl bromide (MeBr) is a highly ... control a wide variety of pests. Under the Montreal ... of the chemicals that contributed to the depletion of ... reduction in the amount of MeBr produced and imported ...
... Progress , Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... this multi-year agreement, Burnham will provide J&JPRD ... to investigate certain drug targets for inflammatory ...
... Mass., Feb. 3, 2009 -- Despite the striking aromatic ... of the nose,s neural circuitry suggests a haphazard patchwork ... likely as not to be neighbors. Inexplicably, this ... even species, with cells that process the same scent ...
Cached Biology News:Methyl bromide alternatives indicated for North Carolina tomato production 2The Burnham Buzz, February 2009 2Neural mapping paints a haphazard picture of odor receptors 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... MEGAscript RNAi Kit is optimized ... mass amounts of ready-to-use dsRNA ... systems. The MEGAscript RNAi Kit ... high-yield transcription technol-ogy and includes ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Using its actuators as building blocks, ... work cell-level ,robotic solutions that are ... Beyond the base ,system, Parker can ... cups, custom structures, and ,guarding., ...
Biology Products: